Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997529 · ClinicalTrials.gov registry record · NA
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT00997529 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00997529, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
A major focus of recent research has been the development of effective ways of sensitizing the patient's immune system to recognize the cancer as foreign. Allogeneic stem cell transplantation represents a novel way of potentially achieving this goal. There is recent evidence that non-myeloablative allogeneic stem cell transplantation provides effective therapy for patients with metastatic renal cell carcinoma. Based on the preliminary reports from other investigators treating patient with breast and ovarian cancer, the investigators of this study would propose treating an expanded cohort of patients with any metastatic solid tumor. The principal endpoints of the trial will include incidence of durable engraftment, quality of hematopoietic and immune reconstitution, extent of donor chimerism, incidence and severity of acute and chronic graft versus host disease (GVHD), and incidence of long-term disease free survival (DFS). The investigators will evaluate the tumor response of patients with stable or progressive disease post-transplant to donor lymphocyte infusions (DLI). The investigators will also study the effects of DLI on T-cell immunity in the recipients.
Interventions
- DRUG nonmyeloablative stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2000-11 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997529
The ClinicalTrials.gov registry entry for NCT00997529 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nonmyeloablative stem cell transplant is the first listed.
NCT00997529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997529 about?
NCT00997529 is a clinical study titled "Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors". A major focus of recent research has been the development of effective ways of sensitizing the patient's immune system to recognize the cancer as foreign. Allogeneic stem cell transplantation represents a novel way of potentially achieving this goal. There is recent evidence that non-myeloablative a...
What is the current status of trial NCT00997529?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2000-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00997529?
The interventions under investigation include: nonmyeloablative stem cell transplant (DRUG).
Who is sponsoring clinical trial NCT00997529?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.